Dyne Therapeutics Executive Compensation Revealed
Ticker: DYN · Form: DEF 14A · Filed: Apr 15, 2025 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | DEF 14A |
| Filed Date | Apr 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Dyne Therapeutics DEF 14A shows exec comp details for 2024, including equity awards for Brumm & Cox.
AI Summary
Dyne Therapeutics, Inc. filed its DEF 14A on April 15, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key executives such as Josh Brumm and John G. Cox, with details on vesting dates and year-end valuations for awards granted in prior years.
Why It Matters
This filing provides transparency into how Dyne Therapeutics compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing disclosing executive compensation and does not present new material risks.
Key Numbers
- 2024 — Fiscal Year End (Executive compensation details pertain to this year.)
- 20250415 — Filing Date (The date the DEF 14A was filed with the SEC.)
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Filer
- Josh Brumm (person) — Executive
- John G. Cox (person) — Executive
- 0000950170-25-053950 (dollar_amount) — Accession Number
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit shareholder votes and provides detailed information about matters to be voted on at a shareholder meeting, including executive compensation, director elections, and other corporate governance issues.
Who are the named executive officers whose compensation is detailed in this filing?
The filing specifically mentions Josh Brumm and John G. Cox, along with 'Other NEOs' (Non-Employee Directors), indicating their compensation details are included.
What types of compensation are typically disclosed in a DEF 14A for executives?
DEF 14A filings typically disclose information on base salary, bonus, stock awards, option awards, non-equity incentive plan compensation, and changes in pension value and nonqualified deferred compensation.
What does 'ecd:FrValAsOfPrrYrEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember' refer to?
This refers to the 'Fiscal Year End Fair Value of Prior Year Equity Awards Granted in Prior Years with Field Vesting Conditions During the Covered Year Member', indicating the valuation of previously granted equity awards that vested during the covered fiscal year.
When is Dyne Therapeutics' fiscal year end?
Dyne Therapeutics' fiscal year ends on December 31st, as indicated by 'FISCAL YEAR END: 1231'.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 15, 2025 by Josh Brumm regarding Dyne Therapeutics, Inc. (DYN).